GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » Price-to-Owner-Earnings

OncoZenge AB (OSTO:ONCOZ) Price-to-Owner-Earnings : (As of May. 16, 2025)


View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Price-to-Owner-Earnings?

As of today (2025-05-16), OncoZenge AB's share price is kr5.26. OncoZenge AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for OncoZenge AB's Price-to-Owner-Earnings or its related term are showing as below:


OSTO:ONCOZ's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.19
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-16), OncoZenge AB's share price is kr5.26. OncoZenge AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.74. Therefore, OncoZenge AB's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-16), OncoZenge AB's share price is kr5.26. OncoZenge AB's EPS without NRI for the trailing twelve months (TTM) ended in was kr-0.74. Therefore, OncoZenge AB's PE Ratio without NRI for today is At Loss.


OncoZenge AB Price-to-Owner-Earnings Historical Data

The historical data trend for OncoZenge AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Price-to-Owner-Earnings Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
- - - - -

OncoZenge AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoZenge AB's Price-to-Owner-Earnings

For the Biotechnology subindustry, OncoZenge AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoZenge AB's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's Price-to-Owner-Earnings falls into.


;
;

OncoZenge AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

OncoZenge AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=5.26/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoZenge AB  (OSTO:ONCOZ) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


OncoZenge AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoZenge AB Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines